Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib
Bjoern Bielec, Hemma Schueffl, Alessio Terenzi, Walter Berger, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol
Topics & Concepts
ProdrugCrizotinibChemistryNitroreductasePharmacologyAnaplastic lymphoma kinaseKinaseTyrosine-kinase inhibitorAlectinibBiochemistryCancerBiologyMedicineSurgeryMalignant pleural effusionGeneticsPleural effusionLung Cancer Treatments and MutationsCancer, Hypoxia, and MetabolismPI3K/AKT/mTOR signaling in cancer